

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 14/205, 7/06, G01N 33/569, A61K 39/106	A1	(11) International Publication Number: WO 96/25430 (43) International Publication Date: 22 August 1996 (22.08.96)
(21) International Application Number: PCT/GB96/00351 (22) International Filing Date: 15 February 1996 (15.02.96) (30) Priority Data: 9502899.9 15 February 1995 (15.02.95) GB (71) Applicant (for all designated States except US): CORTECS LIMITED (GB/GB); The Old Blue School, Lower Square, Isleworth, Middlesex TW7 6RL (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): SMITH, Christopher, John (GB/GB); Isfryn, Tremelrichion Lane, Rhualit, Clwyd LL17 0TE (GB). CLANCY, Robert, Llewellyn [AU/AU]; The University of Newcastle, Pathology, Level 3, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, NSW 2300 (AU). CRIPPS, Allan [AU/AU]; University of Canberra, P.O. Box 1, Belconnen, ACT 2616 (AU). (74) Agents: CHAPMAN, Paul, William et al.; Kilburn & Strode, 30 John Street, London WC1N 2DD (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HELICOBACTER PYLORI ANTIGEN (57) Abstract A novel antigen from <i>H. pylori</i> is provided. Its use in diagnosing <i>H. pylori</i> infection is also disclosed, including methods for said diagnosis, and kits for use in such a method. In addition, novel antigenic fragments of the antigen are provided, as well as vaccines comprising either the antigen or one or more antigenic fragments.		